Hsiao-Yuan Su

Hsiao-Yuan Su

Auto-generated profile, based on publicly available information

Hsiao-Yuan Su

Department of Psychiatry Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Neuropsychopharmacology Reports
Verified
Journal Article
Open access
YSYu-Chih Shen
Yu-Chih Shen
HSHsiao‐Yuan Su
Hsiao‐Yuan Su
Mania is typically associated with psychiatric disorders but can also be secondary to other conditions, such as brain tumors. A notably rapid response to antimanic treatment suggests secondary mania. However, identifying such cases can be challenging. Mrs. M., a 52‐year‐old woman with a history of anxiety and dysthymia, presented with her first manic episode, marked by elevated mood, agitation, reduced sleep, racing thoughts, and grandiose delusions. Her manic symptoms emerged outside the usual age range for mania. She responded remarkably quickly to antimanic medication. Furthermore, her Young Mania Rating Scale (YMRS) score decreased from 36 to 6 within 3 days. This unusual response prompted further investigation, revealing a 46 mm enhancing mass in the medial frontal lobe, affecting the anterior cingulate cortex (ACC). This was confirmed as a meningioma upon surgical removal. The rapid treatment response, combined with the atypical age of onset, raised the suspicion of secondary mania. The discovery of a medial frontal meningioma and its subsequent surgical removal supported this diagnosis. Given the ACC's role in emotional regulation, its involvement likely contributed to the manic symptoms. A swift response to antimanic treatment can indicate secondary mania, such as that caused by a brain tumor. This case highlights the importance of considering secondary causes when mania presents atypically or responds unusually well to treatment.

20 April 2022
Verified
Report
Closed access
PCPo Wei Chen
Po Wei Chen
HHHualien Tzu Chi Hospital
Hualien Tzu Chi Hospital
HSHsiao-Yuan Su
Hsiao-Yuan Su
CWChih-Hsing Wu
Chih-Hsing Wu
JYJih-I Yeh
Jih-I Yeh
SLShu-Man Lin
Shu-Man Lin
Review question / Objective: To determine the association between bisphosphonate use and the risk of incident diabetes and glycemic control in adults with updated evidence from clinical trials and observational studies. Eligibility criteria: The inclusion criteria for studies assessing risk of incident diabetes are as follows: (1) availability of data on bisphosphonate use in individuals without diabetes; (2) evaluation of the risk of diabetes for bisphosphonate users compared with controls; and (3) either clinical trials or observational studies. To assess effects of bisphosphonates on glycemic control, we will include studies with: (1) availability of data on bisphosphonate use in individuals regardless of diabetes state; (2) evaluation of the glycemic parameters, including fasting blood glucose (FBG) or glycosylated hemoglobin (HbA1c), for bisphosphonate users compared with controls; (3) report sufficient data on the change in glycemic parameters (FBG and HbA1c) before and after bisphosphonate use or placebo/comparison use; (4) either clinical trials or observational studies. We will exclude studies with only a single arm without comparison.